Associated tags: Medicine, OGM, Patient, Spectrum, Biology, Genome, Software, SAN, Genomics, Doctor of Philosophy, Research
Locations: SWITZERLAND, MASSACHUSETTS, HAMILTON, NEVADA, LONG, UNITED STATES, UKRAINE, RUSSIA, GEORGIA, SPAIN, LOS ANGELES, RENO, NEW YORK CITY, ISRAEL, SAN DIEGO, CA, US, BEIJING, NEW YORK, CHINA, FLORIDA
Research,
Radboud University Medical Center,
DNA,
Workflow,
Genomics,
Graphics processing unit,
Doctor of Philosophy,
OGM,
NVIDIA,
Computing,
Data analysis,
Vrije Universiteit Brussel,
Video game Stratys is the next evolution of OGM, with significantly and impressively improved throughput.
Key Points:
- Stratys is the next evolution of OGM, with significantly and impressively improved throughput.
- This scalability aligns nicely with recently achieved automated lab workflow for DNA isolation and improved automated analysis and reporting through VIA™ software.
- Smart design also allows higher flexibility and faster processing per sample when compared to the Saphyr system.
- We are excited to see these early access sites partner with us as we extend Stratys adoption across the world.”
Cytogenetics,
Research,
SAN,
Cancer,
Q&A,
Genomics,
DSM-IV codes,
Doctor of Philosophy,
Genome,
OGM,
Genetic disorder,
FACMG 2024 Symposium will take place virtually from January 22 to 25, 2024.
Key Points:
- 2024 Symposium will take place virtually from January 22 to 25, 2024.
- During these four days, customers will showcase their latest research findings using OGM.
- Each day will feature user presentations, a live panel with Q&A, and scientific posters within the virtual exhibition hall.
- After the scientific presentations, the speakers will join for a live panel discussion and Q&A moderated by Dr. Chaubey.
ASD,
Patient,
Medical college,
Spectrum,
DSM-IV codes,
SAN,
Standard of care,
University of Rochester,
University,
Genomics,
SOC,
OGM,
Intellectual disability,
Diagnosis,
Trial of the century The clinical study is designed to compare OGM to current SOC techniques, including concordance, reproducibility, technical success rate and the rate of detecting reportable findings in cases.
Key Points:
- The clinical study is designed to compare OGM to current SOC techniques, including concordance, reproducibility, technical success rate and the rate of detecting reportable findings in cases.
- The published first phase of this multisite study demonstrated OGM’s technical performance and reproducibility across sites versus SOC analysis.
- This second phase extended the study to include additional samples to further assess the technical performance and clinical utility of OGM for postnatal constitutional disorders and to evaluate OGM in prospective samples and in samples from subjects with neurodevelopmental disorders, including developmental delay, intellectual disability and autism spectrum disorder (ASD).
- The key findings are:
OGM increased the rate of finding pathogenic or likely pathogenic (P/LP) variants over that of SOC by a factor of 6% to as much as 50% depending on the patient population as outlined below:
Cytogenetics,
Research,
Symposium,
Hospital,
Genetic variation,
SAN,
Bone marrow,
Breast cancer,
HRD,
Cancer,
Q&A,
Genomics,
DSM-IV codes,
Chromosome,
Drug development,
Laboratory,
Genome,
Doctor of Philosophy,
OGM,
FACMG,
Medical device 2024 Symposium will feature four consecutive days of OGM presentations delivered by 27 different customers worldwide across a wide range of applications in cancer, cell and gene therapy, and constitutional genetic disease.
Key Points:
- 2024 Symposium will feature four consecutive days of OGM presentations delivered by 27 different customers worldwide across a wide range of applications in cancer, cell and gene therapy, and constitutional genetic disease.
- Each day will feature user presentations, a live panel with Q&A, and scientific posters within the virtual exhibition hall.
- On day 2, Bionano will unveil a new product expected to advance cytogenetics and structural variant analysis.
- “At Bionano, we are working to transform the way the world sees the genome,” said Erik Holmlin, PhD, president and chief executive officer of Bionano.
NGS,
LCD,
OGM,
Sale,
Met,
Workflow,
FDA,
Data analysis,
DNA,
Doctor of Philosophy,
IRB,
SAN,
Bank statement,
ATM,
Genomics,
LDT,
Medicare,
Data collection,
Bone marrow,
Video game The Company’s full results for the fourth quarter and the fiscal year ended December 31, 2023 are not yet available.
Key Points:
- The Company’s full results for the fourth quarter and the fiscal year ended December 31, 2023 are not yet available.
- Nanochannel array flowcells sold in the fourth quarter is expected to be 7,980, an estimated increase of 67% over the 4,781 flowcells sold in the fourth quarter of 2022.
- Bionano has not completed preparation of its financial statements for the fourth quarter or full year of 2023.
- Additional information and disclosures would be required for a more complete understanding of Bionano’s financial position and results of operations as of and for the fourth quarter and year ended December 31, 2023.
OGM,
Student,
Research,
Workflow,
ISCN,
SAN,
Doctor of Philosophy,
College,
CLIA,
Chromosome,
Laboratory,
Genomics,
Communication,
International system,
CAP,
Feedback,
Publication,
Medical device SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced a publication outlining the addition of optical genome mapping (OGM) to the International System for Human Cytogenomic Nomenclature (ISCN).
Key Points:
- SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced a publication outlining the addition of optical genome mapping (OGM) to the International System for Human Cytogenomic Nomenclature (ISCN).
- The OGM nomenclature is expected to be published in the 2024 edition of the ISCN guide, a reference volume covering ISCN nomenclature that is utilized worldwide by cytogeneticists, molecular biologists, technicians, and students.
- The ISCN Standing Committee, which is comprised of an international group of experts nominated by their peers, formulated an OGM nomenclature and shared that with an international group of OGM users for their feedback.
- An international nomenclature is essential for clear communication in publications and consistency in databases.
Consortium,
OGM,
SVS,
Radboud University Medical Center,
Workflow,
University,
Bone marrow,
Quality control,
Blood,
University of Oulu,
SAN,
Columbia University,
Laboratory,
LDT,
UZ Leuven,
MD Anderson Cancer Center,
Biomarker,
University of Toronto,
University Health Network,
Algorithm,
Medical device The authors believe that a proactive approach to the development of standards would be beneficial for global laboratories’ understanding of how best to use an OGM workflow.
Key Points:
- The authors believe that a proactive approach to the development of standards would be beneficial for global laboratories’ understanding of how best to use an OGM workflow.
- Consortium members collaboratively outlined a consensus framework designed to provide guidance to laboratories interested in the adoption and implementation of OGM.
- The authors covered considerations that need to be addressed when incorporating OGM into a laboratory, including assessment of clinical utility, proof of principle study, method validation, clinical validation, and implementation.
- The framework addresses these considerations with specific recommendations in three areas: validation, quality control, and analysis and interpretation of variants.
DGV,
NGS,
CMA,
OMIM,
SVS,
OGM,
Research,
Comparison,
SAN,
Doctor of Philosophy,
Database,
Genomics,
VIA,
CNV,
Solve,
Bone marrow,
Medical imaging SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its VIA™ software for applications in constitutional genetic disease.
Key Points:
- SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its VIA™ software for applications in constitutional genetic disease.
- The latest analysis pipeline, Bionano Solve 3.8.1, enhances the sensitivity and specificity for structural variation (SV) detection from OGM data, which, when combined with copy number variant (CNV) analysis capabilities introduced in July 2023, further advance OGM’s leadership in variant detection.
- Together with the enhanced performance for SV and CNV calling, VIA software now enables the most comprehensive visualization, interpretation and reporting of SVs and CNVs from OGM data in constitutional genetic disease research.
- The progress announced today helps the constitutional genetic disease research community go beyond the capabilities of Bionano Access™ software in a way that significantly improves their ability to visualize, interpret and report results in a streamlined process that runs faster than ever.
Clutch (eggs),
CMA,
SVS,
OGM,
Workflow,
Woman,
Doctor of Philosophy,
SAN,
Genomics,
PPV,
Karyotype,
NPV,
Orientation,
KT SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication covering the largest independent prospective prenatal study comparing optical genome mapping (OGM) to a combined workflow of chromosomal microarray analysis (CMA) and karyotyping (KT). The study highlighted OGM’s high analytical concordance with the combined workflow of CMA and KT, and its ability to detect novel pathogenic structural variants (SVs) missed by those methods. The study also highlighted OGM’s potential to provide additional information about SVs and copy number variants (CNVs) compared to CMA and KT.
Key Points:
- The study also highlighted OGM’s potential to provide additional information about SVs and copy number variants (CNVs) compared to CMA and KT.
- Researchers used 200 unique prospective prenatal samples with soft markers (including increased nuchal translucency, nasal bone hypoplasia and mild ventriculomegaly, and structural anomalies) for the study.
- “The use of OGM for the analysis of prenatal samples is an area where we believe our workflow can have tremendous global impact.
- We believe this study marks a milestone in the Chinese prenatal research market as it includes the largest sample size to date for an independent prenatal study using OGM.
Editorial,
Oncology,
In situ hybridization,
CMA,
OGM,
SVS,
Radboud University Medical Center,
Research,
Workflow,
Fluorescence,
DRS,
Bone marrow,
SAN,
Doctor of Philosophy,
Chronic lymphocytic leukemia,
Multiple myeloma,
Genomics,
University,
Karyotype,
CLL,
Cytogenetics,
FACMG,
Growth,
University of Toronto,
Publication,
Acute myeloid leukemia,
KT,
AML,
FISH SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.
Key Points:
- SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.
- “I personally believe the importance of OGM for hematological malignancies research cannot be overstated.
- The papers published in this dedicated issue elegantly illustrate how information provided by OGM surpasses the capabilities of the current tools in cancer research.
- “This special edition of Cancers dedicated to OGM is a significant milestone for the technique and for people in the various fields of genome analysis who are looking for ways to move the community forward.
